ConductScience.org, home

Paper36969044

Editorial: CRISPR advancement in cancer research and future perspectives.

Biagioni A and 1 other. Front Oncol, 2023. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Editorial: CRISPR advancement in cancer research and future perspectives. Papers, record 36969044. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36969044

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Editorial: CRISPR advancement in cancer research and future perspectives.
PubMed
Journal
Front Oncol
PubMed
Year
2023
PubMed
Publication types
Editorial
PubMed
Citations, by iCite
1
iCite
Relative citation ratio, by iCite
0.14
iCite
Revised in PubMed
2023-03-28
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Biagioni AAlessio
2Mohammadinejad RReza

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References9

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132008085EMT signaling: potential contribution of CRISPR/Cas gene editing.Cell Mol Life Sci2020https://conductscience.org/library/papers/32008085PubMed
234445701CAR T-Cell Therapy in Hematological Malignancies.Int J Mol Sci2021https://conductscience.org/library/papers/34445701PubMed
334768751Editing SOX Genes by CRISPR-Cas: Current Insights and Future Perspectives.Int J Mol Sci2021https://conductscience.org/library/papers/34768751PubMed
427882996CRISPR gene-editing tested in a person for the first time.Nature2016https://conductscience.org/library/papers/27882996PubMed
535194172CRISPR in cancer biology and therapy.Nat Rev Cancer2022https://conductscience.org/library/papers/35194172PubMed
636656942CRISPR technology: A decade of genome editing is only the beginning.Science2023https://conductscience.org/library/papers/36656942PubMed
732012858uPAR Knockout Results in a Deep Glycolytic and OXPHOS Reprogramming in Melanoma and Colon Carcinoma Cell Lines.Cells2020https://conductscience.org/library/papers/32012858PubMed
828619109Type II CRISPR/Cas9 approach in the oncological therapy.J Exp Clin Cancer Res2017https://conductscience.org/library/papers/28619109PubMed
925430774Genome editing. The new frontier of genome engineering with CRISPR-Cas9.Science2014https://conductscience.org/library/papers/25430774PubMed

Download CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
38438363Bridging the gap between omics research and dental practice.BDJ Open2024https://conductscience.org/library/papers/38438363

Source PubMed

Download CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36969044

GET https://conductscience.org/api/papers/v1/36969044/authors